TW202135815A - 醫藥組合物 - Google Patents

醫藥組合物 Download PDF

Info

Publication number
TW202135815A
TW202135815A TW109143111A TW109143111A TW202135815A TW 202135815 A TW202135815 A TW 202135815A TW 109143111 A TW109143111 A TW 109143111A TW 109143111 A TW109143111 A TW 109143111A TW 202135815 A TW202135815 A TW 202135815A
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
poloxamer
suspension
alkyl
polyethylene glycol
Prior art date
Application number
TW109143111A
Other languages
English (en)
Chinese (zh)
Inventor
尼瑪 艾克哈文
凱文 邱
埃米爾 斐堤森
Original Assignee
美商 Ｖｉｉｖ 醫療保健公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商 Ｖｉｉｖ 醫療保健公司 filed Critical 美商 Ｖｉｉｖ 醫療保健公司
Publication of TW202135815A publication Critical patent/TW202135815A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW109143111A 2019-12-09 2020-12-07 醫藥組合物 TW202135815A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962945412P 2019-12-09 2019-12-09
US62/945,412 2019-12-09
US202062982305P 2020-02-27 2020-02-27
US62/982,305 2020-02-27

Publications (1)

Publication Number Publication Date
TW202135815A true TW202135815A (zh) 2021-10-01

Family

ID=73834567

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109143111A TW202135815A (zh) 2019-12-09 2020-12-07 醫藥組合物

Country Status (14)

Country Link
US (1) US20230045509A1 (enExample)
EP (1) EP4072520B1 (enExample)
JP (1) JP7703538B2 (enExample)
KR (1) KR20220112771A (enExample)
CN (1) CN114786648A (enExample)
AU (1) AU2020402659A1 (enExample)
BR (1) BR112022010574A2 (enExample)
CA (1) CA3164528A1 (enExample)
ES (1) ES3051362T3 (enExample)
IL (1) IL293566A (enExample)
MX (1) MX2022006940A (enExample)
TW (1) TW202135815A (enExample)
UY (1) UY38982A (enExample)
WO (1) WO2021116872A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑
US20220370451A1 (en) * 2019-10-08 2022-11-24 VIIV HEALTHCARE UK ( No. 5) LIMITED Inhibitors of human immunodeficiency virus replication
WO2025068743A1 (en) * 2023-09-27 2025-04-03 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir
KR20220151655A (ko) * 2020-03-06 2022-11-15 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제
CA3169348A1 (en) * 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
US20230149408A1 (en) * 2020-04-15 2023-05-18 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
WO2022051198A1 (en) 2020-09-01 2022-03-10 Viiv Healthcare Company Combination of cabotegravir and levonorgestrel
JP2024500322A (ja) * 2020-12-07 2024-01-09 ヴィーブ、ヘルスケア、カンパニー 併用療法
US20240425568A1 (en) * 2021-12-17 2024-12-26 Viiv Healthcare Company Combination therapies for hiv infections and uses thereof
EP4719608A1 (en) 2023-05-31 2026-04-08 Gilead Sciences, Inc. Quinazolinyl-indazole derivatives as therapeutic compounds for hiv
CN121909019A (zh) 2023-09-27 2026-04-21 Viiv保健英国第三有限公司 药物组合物
WO2025128498A1 (en) * 2023-12-12 2025-06-19 Viiv Healthcare Company Pharmaceutical compositions
US12594276B2 (en) 2024-02-05 2026-04-07 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
TW202602442A (zh) 2024-03-01 2026-01-16 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 3)有限公司 給藥方案

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550155B2 (en) * 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
PT1874117E (pt) 2005-04-28 2013-10-17 Shionogi & Co Derivado policíclico de carbamoílpiridona possuindo actividade inibidora de hiv-integrasse
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
EP3110422A4 (en) * 2014-02-24 2017-09-06 Board of Regents of the University of Nebraska Compositions and methods for the delivery of therapeutics
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
NZ724644A (en) * 2014-04-11 2023-07-28 Viiv Healthcare Uk No 4 Ltd Triterpenoids with hiv maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent
EP3197430A1 (en) * 2014-09-26 2017-08-02 Glaxosmithkline Intellectual Property (No. 2) Limited Long acting pharmaceutical compositions
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
EP3413913B1 (en) * 2016-02-12 2021-11-24 Cipla Limited Pharmaceutical compositions comprising an anti-retroviral drug and a pharmacokinetic enhancer
ES3035041T3 (en) * 2016-06-23 2025-08-27 Viiv Healthcare Co Compositions and methods for the delivery of therapeutics
JP2019524687A (ja) * 2016-07-01 2019-09-05 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 抗体薬物複合体およびこれを用いた治療方法
TW201906834A (zh) * 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
US20200407393A1 (en) * 2018-03-07 2020-12-31 Glaxosmithkline Intellectual Property (No. 2) Limited Medical Use
EP3774775B8 (en) * 2018-04-11 2023-11-15 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
US20210347813A1 (en) * 2018-04-24 2021-11-11 Viiv Healthcare Uk (No. 5) Limited Compounds with hiv maturation inhibitory activity
US11944611B2 (en) * 2018-07-16 2024-04-02 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV
US11541055B2 (en) 2018-10-24 2023-01-03 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
CN113382737B (zh) * 2018-11-29 2025-06-03 内布拉斯加大学董事会 抗病毒前药及其纳米制剂
UY38559A (es) * 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
EP3934760A1 (en) * 2019-03-06 2022-01-12 GlaxoSmithKline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
EP3962603A1 (en) * 2019-04-30 2022-03-09 ViiV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
KR102932817B1 (ko) * 2019-06-19 2026-03-04 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제로서의 피리도[2,3-d]피리미딘 유도체
JP7719769B2 (ja) * 2019-09-11 2025-08-06 ザ スクリプス リサーチ インスティテュート 抗ウイルスプロドラッグ及びその医薬組成物

Also Published As

Publication number Publication date
WO2021116872A1 (en) 2021-06-17
BR112022010574A2 (pt) 2022-08-23
IL293566A (en) 2022-08-01
EP4072520C0 (en) 2025-09-24
MX2022006940A (es) 2022-07-11
EP4072520A1 (en) 2022-10-19
UY38982A (es) 2021-06-30
EP4072520B1 (en) 2025-09-24
CN114786648A (zh) 2022-07-22
US20230045509A1 (en) 2023-02-09
KR20220112771A (ko) 2022-08-11
JP2023505543A (ja) 2023-02-09
ES3051362T3 (en) 2025-12-26
AU2020402659A1 (en) 2022-06-02
JP7703538B2 (ja) 2025-07-07
CA3164528A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
JP7703538B2 (ja) カボテグラビルを含んでなる医薬組成物
ES2369893T3 (es) Suspensión inyectable de aripiprazol.
TWI738632B (zh) 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
JP2022105625A (ja) 高濃度抗ｃ５抗体製剤
ES2902325T3 (es) Composición farmacéutica oftálmica
US20240182554A1 (en) Protein solution formulation containing high concentration of an anti-vegf antibody
KR20180118136A (ko) Nk-1 수용체 길항제를 포함하는 에멀젼
JP2017528497A (ja) 長時間作用型医薬組成物
US20230321089A1 (en) Combination of cabotegravir and levonorgestrel
WO2025068912A1 (en) Pharmaceutical compositions
AU2023466962A1 (en) Pharmaceutical composition of cabotegravir
US20190231688A1 (en) Method of administering emulsion formulations of an nk-1 receptor antagonist
TW201130826A (en) Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
TWI923576B (zh) 高濃度抗Ａβ原纖維抗體配製物及其使用方法
TW202602442A (zh) 給藥方案
TW202543637A (zh) 醫藥組合物
EA045866B1 (ru) Состав терапевтического антитела
WO2026078715A1 (en) Injectable composition of aprepitant
WO2024227037A1 (en) Long-acting colloidal pharmaceutical compositions of integrase strand transfer inhibitors and related methods